ED@crukcambridgecentre.org.uk
01223 763384
Symposium 2021
ED@crukcambridgecentre.org.uk
01223 763384
Symposium 2021
Published: 09th June, 2021
A new device to detect the early signs of cancer is being offered for the first time to GP patients in the UK, via a special mobile testing unit.
Published: 09th June, 2021
Congratulations to Professor Rebecca Fitzgerald, who has been elected as an EMBO member in recognition of her outstanding life science research.
Published: 07th June, 2021
Age is the most important risk factor for bowel cancer but many genetic and lifestyle risk factors have been identified. There is interest in whether information about these factors could be used to improve screening programmes for bowel cancer. In this research, funded by Bowel Cancer UK and led by Dr Juliet Usher-Smith, scientists at the Universities of Cambridge and Sheffield have been assessing the potential value of identifying people at higher and lower risk of bowel cancer – a process called risk stratification.
Published: 02nd June, 2021
The results of a pilot first-in-human clinical trial demonstrate that using a spectral endoscopy, rather than conventional white-light, gives a more detailed, high-contrast image, helping to differentiate between healthy and cancerous cells more easily.
Published: 04th May, 2021
Rebecca Fitzgerald, Professor of Cancer Prevention and co-lead of the Early Detection Programme, was one of the experts consulted by parliament to consider how to prepare for a changing world.
As part of the Parliamentary Office of Science and Technology's Horizon Scanning process, 30 areas of change were identified that will help the UK Parliament prepare for the future.
Published: 26th April, 2021
A new study, led by Dr Serena Nik-Zainal, has shown a new way to identify tumours that could be sensitive to particular immunotherapies. Developed using data from thousands of NHS cancer patient samples sequenced through the 100,000 Genomes Project, the MMRDetect clinical algorithm makes it possible to identify tumours that have ‘mismatch repair deficiencies’ and then improve the personalisation of cancer therapies to exploit those weaknesses.
Published: 15th April, 2021
Artificial intelligence (AI) could help free up pathologist time and allow them to focus on diagnosing the most tricky cases of Barrett’s oesophagus, according to a Cancer Research UK-funded study published in Nature Medicine today (15th April 2021).
Published: 07th April, 2021
In an interview in the Cambridge Alumni Magazine, Professor Rebecca Fitzgerald explains the remarkable story of the cytosponge and how her literary hero Sherlock Holmes has inspired her to tackle the challenges of early cancer detection.
Read the full 'Cytosponging' feature in CAM.
Published: 07th April, 2021
Dr Daniel Muñoz Espín has recently been accepted as a Member of the Cambridge Philosophical Society. He gave his welcome lecture to the Society on the subject of Targeting Cellular Senescence in Cancer and Ageing. As global populations continue to age Daniel talks about the move towards more anti- senescent therapies and his research on targeting cellular senescence in cancer and ageing.
Click here to hear the talk.
Published: 07th April, 2021
We are delighted to share a fascinating series of discussions and talks from the BEST3 event giving an in-depth look at the results of the BEST3 trial, the use of the Cytosponge for detection of Barrett's oesophagus in primary care, and the implications for:
• Primary care professionals
• Pathologists
• Health researchers and research nurses
• The general public
Click here to select talks on subjects including the trial findings, a patient perspective, a health economics analysis, the GP perspective and pathology and artificial intelligence in BEST 3.